Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.

Avgerinos I. et al, (2023), Diabetes Obes Metab

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.

Karagiannis T. et al, (2022), Diabetologia

Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.

Avgerinos I. et al, (2021), Diabetes Obes Metab

Correction to: Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.

Tremblay J. et al, (2021), Diabetologia

Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.

Tremblay J. et al, (2021), Diabetologia

Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis.

Avgerinos I. et al, (2021), Diabetes Obes Metab

Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis.

Tsapas A. et al, (2021), Diabetes Obes Metab

Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.

Yu J. et al, (2021), Cardiovasc Res

Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.

Avgerinos I. et al, (2021), Diabetes Obes Metab, 23, 822 - 831

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.

Tsapas A. et al, (2021), Ann Intern Med, 174

Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study.

Chan JCN. et al, (2021), Diabetes Obes Metab, 23, 245 - 251

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.

Matthews DR. et al, (2020), Diabetes Obes Metab, 22, 2199 - 2203

Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes.

Matthews D. et al, (2020), Diabetes Ther, 11, 2465 - 2476

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.

Tsapas A. et al, (2020), Ann Intern Med, 173, 278 - 286

Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.

Katulanda P. et al, (2020), Diabetologia, 63, 1440 - 1452

Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.

Katulanda P. et al, (2020), Diabetologia, 1 - 13

ADVANCE.

Matthews DR., (2020), Diabetes Obes Metab, 22 Suppl 2, 3 - 4

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.

Ohkuma T. et al, (2020), Diabetes Obes Metab, 22, 530 - 539

Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.

Avgerinos I. et al, (2020), Diabetes Obes Metab, 22, 335 - 345

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.

Matthews DR. et al, (2019), Lancet, 394, 1519 - 1529

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?